{"contentid": 488354, "importid": NaN, "name": "GSK stops Phase II feladilimab trial", "introduction": "UK pharma major GlaxoSmithKline today announced that, following a recommendation by the Independent Data Monitoring Committee, it has taken the decision to stop enrolling patients in the Phase II INDUCE-3 trial, including discontinuing treatment with feladilimab.", "content": "<p>UK pharma major GlaxoSmithKline (LSE: GSK) today announced that, following a recommendation by the Independent Data Monitoring Committee, it has taken the decision to stop enrolling patients in the Phase II INDUCE-3 trial, including discontinuing treatment with feladilimab.</p>\n<p>The INDUCE-3 study is investigating feladilimab in combination with Merck &amp; Co&rsquo;s (NYSE: MRK) Keytruda (pembrolizumab) versus placebo in combination with pembrolizumab in patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma.</p>\n<p>GSK has also made the decision to stop the INDUCE-4 Phase II trial, a study investigating feladilimab versus placebo in combination with pembrolizumab and chemotherapy.</p>\n<p>The totality of the data will be evaluated to assess the impact on the overall clinical development program for feladilimab.</p>\n<p>GSK shares were trading 1.5% lower in London on Thursday at 1,270.00 pence</p>\n<p>The INDUCE-3 and INDUCE-4 studies are conducted under an agreement between GSK and Merck &amp; Co.</p>", "date": "2021-04-15 11:54:00", "meta_title": "GSK stops Phase II feladilimab trial", "meta_keywords": "GlaxoSmithKline, Feladilimab, Phase II, Keytruda, Cancer, Had and neck, Carcinoma, Merck & Co", "meta_description": "GSK stops Phase II feladilimab trial", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-15 11:52:59", "updated": "2021-04-15 12:06:24", "access": NaN, "url": "https://www.thepharmaletter.com/article/gsk-stops-phase-ii-feladilimab-trial", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "gsk_glaxosmithkline_hq_large.jpg", "image2id": "gsk_glaxosmithkline_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology, Oncology", "topic_tag": "Drug Trial, Research", "geography_tag": "UK, USA", "company_tag": "GlaxoSmithKline, Merck & Co", "drug_tag": "feladilimab, Keytruda, pembrolizumab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-15 11:54:00"}